Robert Lin

Company: Avista Therapeutics

Job title: Chief Executive Officer

Bio:

Rob Lin, PhD, CFA currently serves as the CEO of Avista Therapeutics and a board member of Avista and BlueSphere Bio.  As a VC with UPMC Enterprises, he led the team’s investments in SparingVision, Code Biotherapeutics, Ring Therapeutics, Avista, BlueSphere, and VegaVect, Inc.

Seminars:

Exploring the Benefits of Direct Administration to Lower Dose & Cost 9:00 am

Evaluating systemic and direct routes of administration for vector therapy Outlining the workflow to implement direct administration for CNS indications Elevating the safety and cost benefits of direct administrationRead more

day: Conference Day Two

Utilizing AI to Accelerate Rational Development: How can AI Optimize Gene Therapy Vectors? 11:30 am

Developing effective vector therapies in a time- and cost-efficient manner is key to propelling vector therapy’s potential. AI and machine learning are already streamlining therapeutic development in many fields. Capitalizing on the progression of AI is a great avenue to enhance the efficiency of vector therapy design and development. Given AI’s emerging role in this…Read more

day: Pre-Conference Workshop Day